Journal Article

Humoral and cellular immune responses on SARS-CoV-2 vaccines in patients with anti-CD20 therapies: a systematic review and meta-analysis of 1342 patients

Moor, Matthias B, Born, Alexander, Limacher, Andreas, Horn, Michael P, Maurer, Britta, Hirzel, Cedric, Schietzel, Simeon, Sidler, Daniel, Anderegg, Manuel

2022

Overview

BackgroundImmune responses on SARS-CoV-2 vaccination in patients receiving anti-CD20 therapies are impaired but vary considerably. We conducted a systematic review and meta-analysis of the literature on SARS-CoV-2 vaccine induced humoral and cell-mediated immune response in patients previously treated with anti-CD20 antibodies.MethodsWe searched PubMed, Embase, Medrxiv and SSRN using variations of search terms ‘anti-CD20’, ‘vaccine’ and ‘COVID’ and included original studies up to 21 August 2021. We excluded studies with missing data on humoral or cell-mediated immune response, unspecified methodology of response testing, unspecified timeframes between vaccination and blood sampling or low number of participants (≤3). We excluded individual patients with prior COVID-19 or incomplete vaccine courses. Primary endpoints were humoral and cell-mediated immune response rates. Subgroup analyses included time since anti-CD20 therapy, B cell depletion and indication for anti-CD20 therapy. We used random-effects models of proportions.FindingsNinety studies were assessed. Inclusion criteria were met by 23 studies comprising 1342 patients. Overall rate of humoral response was 0.40 (95% CI 0.35 to 0.47). Overall rate of cell-mediated immune responses was 0.71 (95% CI 0.57 to 0.87). A time interval >6 months since last anti-CD20 therapy was associated with higher humoral response rates with 0.63 (95% CI 0.53 to 0.72) versus <6 months 0.2 (95% CI 0.03 to 0.43); p=0<01. Similarly, patients with circulating B cells more frequently showed humoral responses. Anti-CD20-treated kidney transplant recipients showed lower humoral response rates than patients with haematological malignancies or autoimmune disease.InterpretationPatients on anti-CD20 therapies can develop humoral and cell-mediated immune responses after SARS-CoV-2 vaccination, but subgroups such as kidney transplant recipients or those with very recent therapy and depleted B cell are at high risk for non-seroconversion and should be individually assessed for personalised SARS-CoV-2 vaccination strategies. Potential limitations are small patient numbers and heterogeneity of studies included.FundingThis study was funded by Bern University Hospital.

• Publisher: EULAR,BMJ Publishing Group LTD,BMJ Publishing Group
• Subject: Antibodies / Antibodies, Viral / antirheumatic agents / autoimmune diseases / Automation / Bias / Blood cancer / Coronaviruses / COVID-19 / COVID-19 Vaccines / Digital Object Identifier / Disease / Humans / Immune response / Immunity, Cellular / Immunotherapy / Infections / Lymphocytes / Manufacturers / Meta-analysis / Monoclonal antibodies / Response rates / rituximab / SARS-CoV-2 / Serology / Severe acute respiratory syndrome coronavirus 2 / Systematic review / Targeted cancer therapy / vaccination